Is HEMO or CIR more profitable?

Circassia Group's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hemogenyx Pharmaceuticals N/A -2,807.75% -37.79% Circassia Group N/A N/A N/A

Is HEMO or TILS more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hemogenyx Pharmaceuticals N/A -2,807.75% -37.79% Tiziana Life Sciences N/A N/A N/A

Which has higher valuation and earnings, HEMO or VSN?

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemogenyx Pharmaceuticals N/A N/A -£6.89K -£170.60 N/A Verseon N/A N/A N/A -£14.30 N/A

Is HEMO or VSN more profitable?

Verseon's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hemogenyx Pharmaceuticals N/A -2,807.75% -37.79% Verseon N/A N/A N/A

Which has preferable valuation & earnings, FARN or HEMO?

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Faron Pharmaceuticals Oy N/A N/A -£60.23M -£22.07 N/A Hemogenyx Pharmaceuticals N/A N/A -£6.89K -£170.60 N/A

Is FARN or HEMO more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Hemogenyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals Oy N/A 45.13% -70.00% Hemogenyx Pharmaceuticals N/A -2,807.75% -37.79%

Which has better valuation and earnings, MPH or HEMO?

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mereo BioPharma Group plc (MPH.L) N/A N/A N/A -£128.00 N/A Hemogenyx Pharmaceuticals N/A N/A -£6.89K -£170.60 N/A

Is MPH or HEMO more profitable?

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group plc (MPH.L) N/A N/A N/A Hemogenyx Pharmaceuticals N/A -2,807.75% -37.79%

Hemogenyx Pharmaceuticals (HEMO) Competitors

GBX 722 -2.00 (-0.28%)

As of 12:25 PM Eastern

Compare

HEMO vs. CIR, TILS, VSN, FARN, and MPH

Should you buy Hemogenyx Pharmaceuticals stock or one of its competitors? MarketBeat compares Hemogenyx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hemogenyx Pharmaceuticals include Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), Faron Pharmaceuticals Oy (FARN), and Mereo BioPharma Group plc (MPH.L) (MPH). These companies are all part of the "biotechnology" industry.

How does Hemogenyx Pharmaceuticals compare to Circassia Group?

Hemogenyx Pharmaceuticals (LON:HEMO) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Circassia Group's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%
Circassia Group	N/A	N/A	N/A

Circassia Group has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score.

Company	Overall Sentiment
Hemogenyx Pharmaceuticals	Neutral
Circassia Group	Neutral

Summary

Circassia Group beats Hemogenyx Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Hemogenyx Pharmaceuticals (LON:HEMO) and Tiziana Life Sciences (LON:TILS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%
Tiziana Life Sciences	N/A	N/A	N/A

Tiziana Life Sciences has lower revenue, but higher earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Tiziana Life Sciences'average media sentiment score.

Company	Overall Sentiment
Hemogenyx Pharmaceuticals	Neutral
Tiziana Life Sciences	Neutral

Summary

Tiziana Life Sciences beats Hemogenyx Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Verseon?

Hemogenyx Pharmaceuticals (LON:HEMO) and Verseon (LON:VSN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company	Overall Sentiment
Hemogenyx Pharmaceuticals	Neutral
Verseon	Neutral

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A
Verseon	N/A	N/A	N/A	-£14.30	N/A

0.2% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Verseon's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%
Verseon	N/A	N/A	N/A

Summary

Hemogenyx Pharmaceuticals and Verseon tied by winning 3 of the 6 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

In the previous week, Faron Pharmaceuticals Oy had 2 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 2 mentions for Faron Pharmaceuticals Oy and 0 mentions for Hemogenyx Pharmaceuticals. Faron Pharmaceuticals Oy's average media sentiment score of 1.14 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Positive
Hemogenyx Pharmaceuticals	Neutral

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are held by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Faron Pharmaceuticals Oy has a beta of 1.109, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Summary

Faron Pharmaceuticals Oy beats Hemogenyx Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	-£128.00	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Mereo BioPharma Group plc (MPH.L)	Neutral
Hemogenyx Pharmaceuticals	Neutral

0.2% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Mereo BioPharma Group plc (MPH.L) beats Hemogenyx Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

Get Hemogenyx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HEMO vs. The Competition

Export

Metric	Hemogenyx Pharmaceuticals	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£46.39M	£461.59M	£6.49B	£2.77B
Dividend Yield	N/A	3.87%	2.67%	6.12%
P/E Ratio	-4.23	3.14	20.30	365.54
Price / Sales	N/A	6,606.57	517.33	87,173.10
Price / Cash	2.05	13.13	42.35	27.85
Price / Book	2,930.69	83.47	9.73	7.68
Net Income	-£6.89K	-£96.07M	£3.56B	£5.89B
7 Day Performance	3.44%	-1.70%	-3.19%	-0.55%
1 Month Performance	6.18%	0.74%	-0.11%	3.15%
1 Year Performance	309.41%	70.06%	25.29%	73.57%

Hemogenyx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HEMO Hemogenyx Pharmaceuticals	N/A	GBX 722 -0.3%	N/A	+303.3%	£46.39M	N/A	N/A	14	Gap Up
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11	Positive News
VSN Verseon	N/A	N/A	N/A	N/A	£112.24M	N/A	N/A	N/A	Gap Up
FARN Faron Pharmaceuticals Oy	N/A	GBX 46 -4.2%	N/A	-80.6%	£91.78M	N/A	N/A	34

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HEMO) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hemogenyx Pharmaceuticals (HEMO) Competitors

HEMO vs. CIR, TILS, VSN, FARN, and MPH

How does Hemogenyx Pharmaceuticals compare to Circassia Group?

Summary

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Summary

How does Hemogenyx Pharmaceuticals compare to Verseon?

Summary

How does Hemogenyx Pharmaceuticals compare to Faron Pharmaceuticals Oy?

Summary

How does Hemogenyx Pharmaceuticals compare to Mereo BioPharma Group plc (MPH.L)?

Summary

Media Sentiment Over Time

HEMO vs. The Competition

Hemogenyx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hemogenyx Pharmaceuticals (HEMO) Competitors

HEMO vs. CIR, TILS, VSN, FARN, and MPH

How does Hemogenyx Pharmaceuticals compare to Circassia Group?

Do insiders and institutionals have more ownership in HEMO or CIR?

Is HEMO or CIR more profitable?

Which has stronger earnings & valuation, HEMO or CIR?

Does the media prefer HEMO or CIR?

Summary

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Do insiders and institutionals hold more shares of HEMO or TILS?

Is HEMO or TILS more profitable?

Which has stronger earnings and valuation, HEMO or TILS?

Does the media prefer HEMO or TILS?

Summary

How does Hemogenyx Pharmaceuticals compare to Verseon?

Does the media refer more to HEMO or VSN?

Which has higher valuation and earnings, HEMO or VSN?

Do institutionals and insiders hold more shares of HEMO or VSN?

Is HEMO or VSN more profitable?

Summary

How does Hemogenyx Pharmaceuticals compare to Faron Pharmaceuticals Oy?

Is FARN or HEMO more profitable?

Which has preferable valuation & earnings, FARN or HEMO?

Does the media prefer FARN or HEMO?

Do insiders and institutionals have more ownership in FARN or HEMO?

Which has more volatility & risk, FARN or HEMO?

Summary

How does Hemogenyx Pharmaceuticals compare to Mereo BioPharma Group plc (MPH.L)?

Which has better valuation and earnings, MPH or HEMO?

Is MPH or HEMO more profitable?

Does the media favor MPH or HEMO?

Do insiders & institutionals hold more shares of MPH or HEMO?

Summary

Media Sentiment Over Time

HEMO vs. The Competition

Hemogenyx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools